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Proton therapy has advantages and pitfalls comparing with photon therapy in radiation
therapy. Among the limitations of protons in clinical practice we can selectively mention:
uncertainties in range, lateral penumbra, deposition of higher LET outside the target,
entrance dose, dose in the beam path, dose constraints in critical organs close to the
target volume, organ movements and cost. In this review, we combine proposals under
study to mitigate those pitfalls by using individually or in combination: (a) biological
approaches of beam management in time (very high dose rate “FLASH” irradiations in
the order of 100 Gy/s) and (b) modulation in space (a combination of mini-beams of
millimetric extent), together with mechanical approaches such as (c) rotational techniques
(optimized in partial arcs) and, in an effort to reduce cost, (d) gantry-less delivery systems.
In some cases, these proposals are synergic (e.g., FLASH and minibeams), in others they
are hardly compatible (mini-beam and rotation). Fixed lines have been used in pioneer
centers, or for specific indications (ophthalmic, radiosurgery,…), they logically evolved to
isocentric gantries. The present proposals to produce fixed lines are somewhat
controversial. Rotational techniques, minibeams and FLASH in proton therapy are
making their way, with an increasing degree of complexity in these three approaches,
but with a high interest in the basic science and clinical communities. All of them must be
proven in clinical applications.
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Mazal et al. Biomechnical Synergies vs Proton Therapy PitfallsINTRODUCTION: ADVANTAGES AND
PITFALLS IN PROTON THERAPY
Proton therapy has been evolving as the reference for conformal
radiation therapy for decades and, in spite of an exponential
growth, it is still limited to less than 1% of the patients
treated with radiation therapy even in high-income countries.
The primary advantages of proton therapy—compared
with conventional photon beams—that justify its use and
development are:
1. there is not a maximum of dose in the path of a beam;
2. it may have a small lateral penumbra in the path of a beam;
3. it is possible to irradiate homogeneously (or with a controlled
inhomogeneity) a target in depth even with a single beam;
4. the range of particles can be placed anywhere by changing the
energy of the beam;
5. there is a high gradient of dose after the range;
6. there is no practical dose beyond the distal gradient, i.e., the
beam stops;
7. the radiobiological efficiency is managed in clinics with a
rather low risk.
But there are also pitfalls:
1. the entrance dose can be higher than the usual with photon
beams (no skin sparing), depending on parameters such as
the proximity of the target volume to the skin, the thickness
of the target, the delivery technique;
2. the lateral penumbra in depth, at depths close to the range
and in the region of the target volume, can be higher than
mid-energy photon beams (e.g., 6 MV) as such used in
rotational VMAT techniques with photons;
3. there are large uncertainties on the position of the range in
complex tissues including inhomogeneities, imposing large
margins to get robustness of plans, and placing the higher
Linear Energy Transfer (LET) beyond the target limits.
4. There are complex dose distributions and large uncertainties
beyond implanted materials such as metallic screws, rods,
prosthesis, …;
5. There is a neutron dose in the tissues around the target, even
far from it; it has been reduced in the evolution of proton
systems from passive to pencil beam, but still there,
comparing with photons beams with energies lower than
10 MV;
6. It is complex to irradiate moving targets, even more when
using scanned pencil beams, in spite of specific protocols of
repainting and organ movement management (interplay
effect, undesirable doses beyond the target,…);
7. Capital and operational costs are high, uptimes are
sometimes limited and it is difficult to easily have backups
in case of system failure.
In Figure 1, some of these advantages and pitfalls
are presented for a single proton beam in particular
compared to a single photon beam and for a final clinical
dose distribution.Frontiers in Oncology | www.frontiersin.org 2In practice, there are clinical cases where the dose gradient
between a target and a close critical organ maybe better achieved
with photon beams. But the integral dose distribution will always
be easier to optimize with proton beams, given their finite range
(no exit dose) that reduce the irradiation to large volumes of
healthy tissues.
The advantages offered by proton therapy are stronger than
the pitfalls, justifying the fact that more than 200,000 patients
have been treated with protons in the world to date with more
than 20,000 new treatments added per year. Proton therapy is a
rational choice among the existing tools in radiation therapy for
some clinical targets: pediatrics, ophthalmic, base of the skull,
reirradiations. Most of the other clinical sites in radiation
oncology are under investigation to quantify the real clinical
advantage of the use of protons and the associated cost, through
studies of tumor control, complications and quality of life.
Concepts like “model-based approach” are used to evaluate
individual cases, and Qualy, quality of life, cost-benefit and
similar ones for a population-based study.
The use of photon beams is also still evolving, many more
scholars are working actively in the photon therapy space and the
pace of innovation is high. The development of any modality in
radiation therapy (photons, electrons, neutrons, protons, heavy
particles …) can be synergic and not opposed between them.
Innovations such as the use of online magnetic resonance imaging,
adaptive therapy and the combination with immunological
approaches are examples of major improvements to be shared.
Several papers are included in this special issue to deal with
some of the proton therapy pitfalls, trying to reduce or to
eliminate them, or at least to control and mitigate their effect.
In this work we want to review and address biological and
mechanical proposals to mitigate most of the mentioned pitfalls,
using particular approaches to distribute the dose in space
(minibeams) and time (FLASH effect) as well as to reduce
complexity (rotational therapy) and cost (gantry less facilities),
to make proton therapy more accessible to the benefit of more
cancer patients.BIOLOGY: REVISITING RADIATION
BIOLOGY TO IMPROVE HEALTHY
TISSUE PROTECTION
The location of the tumors and the nature of the treatments
inevitably leads to a certain degree of undesired effects in
surrounding tissues. Proton minibeam radiation therapy
(pMBRT) and ultra-high dose rate (FLASH) radiotherapy
(FLASH RT) are two innovative radiotherapy modalities where
the potential to reduce normal tissue toxicity have already been
demonstrated, compared to standard radiotherapy, potentially
revolutionizing the radiotherapy field.
Recently several reviews on the tissue sparing and tumor
control with Flash have been published, including a few oriented
towards proton therapy (1). One of us and co-authors presented
a review of minibeams and FLASH radiation therapy, with both
approaches working independently or in synergy (2).January 2021 | Volume 10 | Article 613669
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on these subjects and how they are linked to advances in ongoing
mechanical aspects of proton therapy such as proton arc therapy.
Flash
Recent pre-clinical studies have found that the “new”
methodology named “FLASH”, which consists of delivering
single doses of 5 to 10 Gy in a single microsecond pulse or in
times lower than 100 to 500 ms, produces a dramatic decrease of
damage to normal tissues while keeping the anti-tumoral effect
(3–6). This FLASH effect was described as early as the 1970s for
intestinal tumors and skin lesions. One of the pioneers, J.
Hendry, who, in the 1970s and 1980s, related the amount of
oxygen with the radioprotection of tissues using high intensity
pulsed electron beams, recently rediscussed the clinical potential
application of FLASH and, finally supported the development of
proton experiments while recommending to take care having a
long follow up and a better understanding of parameters and
effects (7, 8). The robustness of the FLASH effect has recently
been reproduced in various animal models, such as mice, rats,
zebrafish, pigs, and cats (5) for several organs such as lung, skin,
gut, and brain (3, 4, 9, 10).
To prove the toxicity limiting capability of FLASH RT,
Favaudon et al., used a lung fibrosis model in mice and
demonstrated that thoracic irradiation of mice with FLASH
dose rates (40–60 Gy/s) reduced the induction of pulmonary
fibrosis when compared with conventional dose rates (0.03 Gy/s)Frontiers in Oncology | www.frontiersin.org 3where 100% of the mice develop lung fibrosis (3). In this study,
they also used a xenograft model of head and neck squamous
carcinoma, a xenograft model of breast cancer, and a syngeneic
model of lung cancer and found that in all three models FLASH
RT was as efficient as conventional radiotherapy in reducing
tumor growth (3).
The reduced radiotoxicity of FLASH RT has also been shown
by the irradiation of the mice abdomen. In a recent work,
Diffenderfer et al., showed that after acute radiation of 10-
week-old C57BL/6J mice with either 15 Gy whole abdominal
FLASH proton RT (789 Gy/s) or standard proton RT (0.9 0.08
Gy/s) acute cell loss and late fibrosis were decreased in the mice
irradiated with FLASH proton therapy, whereas the effect on
tumor growth was similar with the two irradiation modalities
(10). This is in agreement with previous studies where the
protective effect of FLASH RT in the gut was also observed
(11). Using proton beams, Abel et al. (12) reported differences
between FLASH (and FLASH with pulsed beams) vs
“conventional” radiation for doses higher than 15 Gy on the
thorax region of mice using several endpoints such as weight,
dermatitis, lung function and lung fibrosis, as well as gender
differences (female mice having better response to FLASH but no
difference on mode of cell death).
Furthermore, it has also been shown in several studies that
FLASH radiotherapy also has less neurotoxic effects compared to
conventional RT (9, 13–15). Montay-Gruel et al., reported that
mice with whole brain irradiated with FLASH RT experiencedFIGURE 1 | Beams for a treatment of a base of skull tumor: (A) single proton beam; (B) single photon beam; (C) difference between single proton (higher dose in
red) and photon beams (higher dose in blue); (D) combination of photon arcs; (E) combination of proton beams.January 2021 | Volume 10 | Article 613669
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behavioral studies compared to those irradiated with standard
RT (9, 13).
The biological mechanism responsible for the reduced tissue
toxicity following FLASH RT is yet to be fully explained. The
reduced adverse long-term effects of FLASH irradiation observed
in normal tissues compared to conventional dose rates and or
tumor tissues have been explained by the different type and/or
amount of the induced DNA damage. In vitro experiments
suggested that the genomic instability induced in response to
FLASH RT was much lower than at conventional dose rates
(16, 17).
In addition to the DNA damage, several hypotheses have been
proposed to explain the FLASH effect, such as the presence of
free radicals or oxygen depletion that will trigger different
biological responses depending on the status and metabolism
of the cell (18). Oxygen depletion has been proposed to cause
transient hypoxia and radio-resistance, and this is considered as
the underlying mechanism, but in vitro data to support this
assumption has been lacking until recently (19). To test the role
of oxygen in the FLASH effect, Adrian et al., irradiated prostate
cancer cells at different oxygen concentrations using either 600
Gy/s (FLASH) or 14 Gy/min (CONV) (20). Their results showed
that in hypoxic conditions, cell survival increased in the cells
irradiated with FLASH, while in normoxic conditions no
differences were found between FLASH and conventional RT
(20). A recent study by Montay-Gruel et al., proposes that
oxygen depletion at ultra-high dose rates inhibits the
production of reactive oxygen species (ROS) which promote
radio-resistance (9). They report that increasing the local oxygen
concentration reversed the protective effect of FLASH (9).
Furthermore, depletion of ROS using ROS scavengers
sensitize zebrafish embryos to conventional therapy while
having no effect in FLASH RT (9). The oxygen depletion
hypothesis was used to explain the normal tissue radio-
resistance to FLASH RT.
Besides local and transient oxygen depletion, radical-radical
interaction is another hypothesized reason for the FLASH effect.
FLASH irradiation results in a high local radical concentration
available to interact with the DNA (21).
However, if tumors (or partial volumes of the tumors) are
partially, but maybe not fully, hypoxic, how do they react with
FLASH RT? The metabolic reorganization or the absence of
proper antioxidant defenses, frequent in tumor cells, may
accelerate the presence of irradiated induced radicals which
may jeopardize tumor cell viability.
Nevertheless, more studies are necessary to validate these
hypotheses experimentally for a full understanding of the
biological effects induced by FLASH therapy.
The immune system and inflammation have also been
proposed to play a role in FLASH RT protective effect of
normal tissues. In their paper, Favaudon et al., found changes
in the induction of the transforming growth factor beta (TGFb),
a pro-inflammatory signal, which was reduced in FLASH
irradiated mice (3). In addition, previous studies have shown
an increased recruitment of T lymphocytes in tumors treatedFrontiers in Oncology | www.frontiersin.org 4with FLASH-RT (22). Furthermore, a recent study in which they
perform a genome-wide microarray analysis on mice that have
been irradiated either with FLASH or conventional RT showed
that immune system wide activation and maturation was
downregulated in mice following FLASH RT (23). Therefore,
these studies suggest that FLASH irradiation induces the
response of the immune system in the irradiated tissue;
however, the molecular mechanism behind this response
remains to be explained.
Recently, Wardman (24) reviewed 60 years of experience with
pulse radiolysis and highlighted 2 mechanistic approaches for the
differentiated effect on normal versus tissue cells, i.e., the
depletion of a chemical critical to the effect and/or the radical-
radical reactions. Favaudon (25) also reviewed these two
approaches, i.e., oxygen depletion vs radical recombinations,
giving more weight to the second phenomena. He also stated
that in both extremes of anoxia (or deep hypoxia) and hyperoxia
there is no FLASH effect, making it important to know the
oxygen pressure in the tumor and tissues to predict the effect.
The group presented a chemical kinetic model supporting
peroxyl radical recombination as the main effect (26) and,
adding the results from Fouillade et al. (4), they conclude that
part of the differential effect between tumors and healthy tissue
could be related to DNA damage (dependent on oxygen and
radicals) and double strand break repair protein 53BP1 for which
tumors cells have a repair defect.
From the published data, we conclude that the main
hypothesis explaining the FLASH benefit, is based on three
main aspects, i.e., (a) a “window” of Oxygen concentration, (b)
the kinetics of radicals and, (c) an intrinsic differentiation
between tumor and healthy cells related to their DNA damage
repair mechanisms. A correct understanding of the mechanisms
behind FLASH effect may help to establish protocols aiming to
decrease the harmful effects of ionizing radiation by preserving
the healthy tissues surrounding the irradiated tumor while
keeping the curative effect. A first clinical application has been
reported (6) and new clinical trials are being approved.
Furthermore the potential use of FLASH in pediatrics (e.g., in
medulloblastoma) has been cited from studies in juvenile
mice (27).
Mini-Beams
Minibeam radiation therapy (MBRT) is an innovative strategy
for spatially fractionated radiotherapy that consists of using a
series of narrow (sub-millimetric) parallel beams to deliver the
dose. This results in dose profiles consisting of a pattern of peaks
and valleys.
The approach has an old rational with spatially fractionated
“GRID” radiation therapy with photons using patterns of large
peaks and valleys or sectors, both in the 1-cm scale, to spare skin
toxicity with orthovoltage devices (28) and to shrink
malignancies for advanced and palliative cases, with Co´60 and
linacs (29), but not with curative intention.
The rationale behind the new approach is that the smaller the
beam size is, the higher the dose tolerances of the healthy tissue
appears to be, and a curative aim can still be kept. This is knownJanuary 2021 | Volume 10 | Article 613669
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MBRT is less neurotoxic than standard radiotherapy (30–35).
The potential of the minibeams radiotherapy technique was
studied in brain tumor bearing rats that were irradiated using
X-ray minibeams. Deman et al., found that the survival time of
irradiated glioma bearing rats was doubled when compared to
untreated animals (30). This increase in glioma bearing rats’ life
span was similar to the one obtained through other radiotherapy
techniques. However, no brain damage was found on X-ray
minibeams irradiated in healthy rats suggesting healthy tissues
have a higher tolerance to submillimetric spatially fractionated
beams (30). These experiments suggest that X-ray minibeams
can be used in brain tumor radiotherapy.
Prezado et al. modified a small animal irradiator to be able to
perform MBRT experiments. As a proof of concept experiment,
they irradiated a group of rats with standard radiation while the
other group received MBRT, both groups with 20 Gy mean dose
and evaluated 6.5 months after radiation. They found that the
standard RT group have extensive brain damage while in the
MBRT group no significant brain lesions were observed (31). In
vitro studies have shown that MBRT induces clonogenic cell
death of human glioma cell lines (33). In a recent report by the
same group showed that proton MBRT (pMBRT) increases the
therapeutic window for high grade gliomas (34). They showed
that pMBRT causes less neurotoxicity than standard proton
therapy and in addition it significantly reduces tumor growth
(34). This opens the possibility for even more aggressive
irradiation schemes.
In a recent study by Dos Santos et al., they compare the
micro- and nanodosimetric characteristics of three different
MBRT modalities: proton (pMBRT), photon (xMBRT) and
electron (eMBRT). They found that pMBRT was the most
effective at preserving normal tissue since it caused less energy
deposition and lower number of DNA breaks both in peak and
valley cell nuclei (35). Furthermore, pMBRT was also the most
aggressive treatment in the tumors region, as it was associated
with a higher number of complex DNA breaks and higher energy
deposition, and energy per event, at the cell nucleus (35).
As mentioned above several studies have reported the
therapeutic interest of the MBRT at preclinical level, but the
biological mechanisms responsible for the described protection
of healthy tissues are not fully understood to date. Classically, the
protective effect of MBRT on healthy tissues has been associated
with the apparent resistance of normal tissue vasculature to
MBRT (36). Furthermore, it has been proposed that the
efficiency of MBRT on reducing tumor growth is related to a
preferential damaging effect on the tumor vasculature (37).
When applied to the brain of rodents, microbeam irradiation
does not modify blood volume or vascular density (36). In fact,
the endothelial cell lining of the vessels in the microbeam paths
remains intact (37). However, immature blood vessels are more
sensitive to MBRT than mature blood vessels (38). This has led to
the hypothesis that immature blood vessels in the tumor will be
more sensitive to MBRT while the healthy tissue mature blood
vessels will be resistant to MBRT. Several reports have shown
that MBRT affects the tumor vasculature structure, nevertheless,Frontiers in Oncology | www.frontiersin.org 5the effect may vary depending on the tumor type. In general,
MBRT induces a decrease in tumor blood vessels leading to
decrease in perfusion and to tumor hypoxia (39, 40). However, in
a mammary tumor model, MBRT increased pericyte numbers,
suggesting a normalization of the vasculature structure and
tumor oxygenation (41). Although MBRT preferentially affects
the tumor vasculature structure, we shouldn’t restrict the effects
of MBRT to vascular effects only.
A study of the early transcriptomic responses of normal brain
and glioma tissue in rats after MBRT irradiation showed that
inflammation and immunity appear to be major contributors to
MBRT efficacy (42). Pathways related with natural killer cells
(NK) or CD8+ T lymphocytes were particularly represented in
the irradiated tissue. Furthermore, they found changes in genes
such asHMGB1, Toll-like receptors 1, 2, 7, C-type lectins 7A and
CD36 in the irradiated tissue (42). These genes can trigger
activation of innate or adaptive immune cells. Therefore, their
hypothesis is that biochemical changes in irradiated cells, will
activate these genes which in turn will promote inflammation or
an immunological response (42). This is in agreement with data
from Sprung et al. that have previously reported using a genome
transcriptional screening that MBRT in mouse mammal tumors
induced upregulation of immunity-related genes (43). Still more
in vitro and in vivo experiments where the immune response
within healthy tissue and/or tumor is studied in response to
MBRT are necessary to fully understand the mechanisms behind
MBRT. We conclude that there are still a lot of open questions
about the mechanisms of action associated with MBRT.
Although the mechanisms of action and the biological effects
of both FLASH and MBRT are still under study, both radiation
modalities have the potential to become paradigm-changing
technologies in the radiotherapy field. They can open the door
to a new approach to the delivery of curative radiotherapy and
may become an effective treatment for radioresistant tumors.
The Dose Matter: The Dosimetry of FLASH
and Mini-Beams
The accurate measurement of the dose delivered in a FLASH
irradiation with photons, protons or electrons is a challenging
task mainly due to the high dose-rate beams employed in this
radiotherapy technique. Because of this, redundant
measurements are usually performed with dosimeters whose
response is nearly independent of the dose-rate (44).
As in the case of conventional radiotherapy, ionization
chambers may be employed to measure the absolute dose, but
with some caution. For instance, it has been stated by Petersson
et al. (45) that the factors that correct the raw charge collected by
the dosimeter in a pulsed electron FLASH irradiation depend on
the dose per pulse rather than on the dose-rate.
Faraday cups have also been employed as a dosimeter in
FLASH radiotherapy. In this case, the integral charge measured
is used to validate the ionization chamber measurements, as
shown in different studies (10, 46).
Among the dosimeters with a response independent of the
dose rate, radiochromic films are commonly employed to
provide a redundant verification of the dose delivered asJanuary 2021 | Volume 10 | Article 613669
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(48). Also, alanine pellets have been satisfactorily employed
together with radiochromic films to perform independent dose
verifications in the first clinical FLASH treatment of a human
patient (6). Other dose-rate independent dosimeters that have
been employed for the measurement of ultrahigh dose-rate
beams are the PTW microdiamond, the LYNX 2D scintillator
the TLD-100 and the Methyl Viologen (44). A comprehensive
review of dosimeters for FLASH including charge-based,
chemicals and luminescence detectors has been presented
recently (49) with interesting figures of merit in a spider chart
diagram for each of them, underlying the importance of the
luminescence methods for resolution in time and additional
performances on measuring Oxygen tension and LET.
Finally, some experiments have been carried out to achieve
real time monitoring of FLASH irradiations. For instance,
Diffenderfer et al. (10) employed a NaI gamma detector to
relate the prompt gamma rays detected to the dose rate of the
irradiation while Oraiqat et al. (50) have stated that an ionizing
radiation acoustic imaging technique may be employed to
perform real-time deep tissue dosimetry.
The dosimetry of proton minibeams radiation therapy is
challenging due to the fact that it should characterize the
inhomogeneous entrance spatial dose distribution as well as
the homogenous part of the dose distribution. The entrance
dose distribution presents marked spatial variations in the
millimetric and submilimetric scale thus a high spatial
resolution dosimeter should be employed. On the other hand,
the homogeneous part of the beam does not present markedly
spatial variations thus conventional dosimeters such as
ionization chambers may be used. For this reason, a two-step
protocol has been proposed by Peucelle et al. (51) in order to
measure proton minibeams obtained by means of a multi-slit
collimator. The first step consists in absolute dose measurements
performed with a thimble ionization chamber and the second
step is performed with radiochromic films to characterize the
peak-to-valley dose ratios.
Radiosurgery diodes have been employed as an alternative to or
together with radiochromic films for measurements in the high
modulated entrance dose region. In the work of DeMarzi et al. (52),
the high modulated entrance region is characterized by performing
measurements with a radiosurgery p-type silicon diode.
Microdiamond diodes have also been proposed and evaluated in
the works of Meyer et al. (53) and Farr et al. (54). Also, a
microdiamond diode has been employed to characterize carbon
and oxygen mini-beams in the work of Martinez-Rovira et al. (55).
Finally, some experiences have been carried out with gel
dosimetry as in the work of Annabell et al. (56), where
fluorescent microscopy is employed to achieve higher spatial
resolution dose measurements.
The Time Factor in Beam Delivery for
FLASH: The Pulsed Structure of Clinical
Beams and Its Relationship With the
Kinetics of the Physicochemical Processes
While it is usual to talk about the high dose rate to achieve
FLASH, it is important to understand how this dose is deliveredFrontiers in Oncology | www.frontiersin.org 6in time, in particular the pulsed structure of the beam. In two
extremes, we can mention the “continuous” irradiation provided
by a cyclotron (acceleration at several MHz), and the low
frequency pulses of a synchrotron (a few Hz) and
synchrocyclotrons (typically 1 KHz), modified by different
extraction methods. The latter is gaining industrial interest
from the perspective to make compact accelerators.
Internally, a synchrocyclotron varies the frequency of
acceleration to be synchronized with the particle mass when it
acquires energy. Here we use the “S2C2 Proteus One
synchrocyclotron” (IBA, Leuven) as an example. We measured
the beam intensity arriving at the isocenter as a function of time
in a clinical condition (Figure 2). The accelerating frequency
varies from 90 to 30 MHz. At extraction, there are pulses of about
10 µs wide (Figure 2A) each 1 ms (Figure 2B), i.e., 1 KHz pulses.
In Figure 2B, we superposed published data (26) on the O2
evolution from a concentration of 50 µmol/L, as if 10 Gy were
delivered at 106 Gy/s in the first pulse of 10 µs wide. The potential
interaction with the pulsed beam must be evaluated in any
experimental study (e.g., delivering the 10 Gy in 10 or 100
pulses) for all the elements involved (Oxygen, radicals, etc.).
Other patterns of dose delivery in time must be considered. In
some systems the dose deposition in a single “spot” is fractionated
in two to three parts so a feedback system can measure and control
the delivery of an accurate total integrated charge for the spot. At a
larger scale of time, when using a “pencil beam scanning system”,
the dose at a given point in the medium will have contributions
from contiguous points and lines (related to scanning times) and
layers (related to time to change the beam energy). In an even
larger scale of time, if more than one beam is planned, several
seconds or minutes are required to rotate the gantry and/or a couch
to position the next beam and even more time is added if any
verification of the new beam and patient position is required. The
possibility to deliver FLASH in a very small number of fractions will
add the scale of a daily difference between irradiations.
It is of the utmost importance to evaluate in the research
programs these scales of time in particular related to the
chemical and biological process mentioned before.MECHANICS: THE ADVANTAGES AND
LIMITS OF ARCS AND GANTRY-LESS
PROTON BEAMS
Proton arc therapy is under consideration nowadays to reduce
calculation complexity and uncertainties, as well as to optimize
the deposition of high LET in tissues. But proton gantries are
much more cumbersome and expensive than gantries for photon
beams. There is a renewed interest to evaluate fixed lines and
rotate the patient to reduce costs. Both approaches, arcs and fixed
lines, have advantages and pitfalls we evaluate here.
Proton Arc Therapy (PAT)
The notion of rotating the proton gantry during beam delivery,
in a similar fashion as it is done for Volume Modulated Arc
Therapy (VMAT) using photons, has been studied in detail byJanuary 2021 | Volume 10 | Article 613669
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study (57), which used a rotational phantom to show the
favorable physical properties of protons over electrons, most
studies have been limited to dosimetric calculations in patients or
phantoms. These studies showed that protons arcs have indeed a
better longitudinal dose profile than photons (58, 59), and that
increasing the number of incoming angles could have a positive
impact on the resulting dose distribution, further reducing out-
of-target dose (60–62) and secondary neutron dose for passively
scattered protons (63).
However, none of these studies addressed in detail the
feasibility and practical aspects of the proposed solutions.
Treatment planning was typically performed with standard
clinical software (by simply selecting an arbitrarily large number
of fields). The effect of energy layer switching time (ELST),
preventing different energy layers from being delivered
simultaneously, from a single control point, was not contemplated.
A group at the University of Pennsylvania (Philadelphia, PA)
did publish some work on the feasibility of delivering proton arcs
using passively scattered (PS) beams (64, 65) but with the global
market moving inevitably towards pencil beam scanning (PBS)
solutions, no new developments involving PS beams were
realistic at the time. The same group also explored the
feasibility of arc techniques with PBS (66), showing that, with
an adequate range selection system, single- and dual-energy
proton arcs (named Proton Modulated Arc Therapy, or
PMAT) could achieve similar dose coverage and organ-at-risk
sparing capabilities as full-coverage 2-field and 4-field intensity-
modulated proton therapy (IMPT) plans (67). The same study
also showed limited improvement by using fully modulated arcs,
warning that existing planning systems might not be able toFrontiers in Oncology | www.frontiersin.org 7produce optimal proton arc therapy plans by simply combining
an arbitrarily large number of field angles in an IMPT plan, and
that specific treatment-planning algorithms for proton arc
therapy, either developed in-house (68, 69) or as an addition
to existing systems (70) are probably required.
In 2016, a research group at Beaumont Health (Royal Oak,
MI) published an article describing a PAT solution named
SPArc, for Spot-scaning Proton Arc Therapy (70). It is based
on a patented algorithm that optimizes the number of arc control
points and the number of energy layers delivered from each
angle. The algorithm was implemented in Raystation (RaySearch
laboratories AB, Stockholm, Sweden) and used to plan two
example patient cases, showing some potential for dose
reduction in healthy tissues at a cost of increased delivery and
treatment planning times. These time increased by a factor of ~2
and ~10, respectively, in comparison with equivalent static IMPT
plans. This team has since published several studies analyzing
possible dosimetric outcomes of SPArc in various tumor sites:
prostate (71), non-small cell lung cancer (72), whole brain
irradiation (73), head and neck (74) and left-side breast (75).
This last location has been also explored by other teams (76).
Table 1 summarizes the most relevant data from these studies.
In general, it is hard to produce convincing evidence
comparing two techniques based solely on treatment planning.
The physical or biological rationale supporting superiority of a
technique over another must be absolutely clear: in other words,
these kind of studies have to prove that not only is SPArc better
than IMPT in a selection of cases, but also that IMPT could not
produce equivalent results if used differently (different planning
objectives, different choice of fields, etc.). Also, as is usually the
case with proton therapy, it is often unclear, and not necessarilyFIGURE 2 | Measurement at a fixed spot in a media when delivering protons with a scanned beam from a synchrocyclotron: (A) single spot; (B) a sequence of
spots delivered in a same point at an extraction frequency of 1 kHz, superposed with the effect on oxygen (O2) from a first pulse (see text); (C) effect cumulated dose
in a point given by different lines scanned in a single layer (each packet is a line, the next packet is a contiguous line); (D) change of a layer in depth with a larger time
to change energy (here about 1 sec). Measurements have been performed with a CeGAG scintillator coupled to a S13360-6075CS SiPM from Hamamatsu, read
with a digital Picoscope.January 2021 | Volume 10 | Article 613669
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clinically relevant improved effects. Tumor-control probability
(TCP) and normal-tissue complication probability (NTCP)
models are therefore useful to prove this point, waiting for real
clinical trials.
All five studies published to date by the Beaumont team show
a clear potential of the SPArc technique to reduce out-of-target
(integral) doses, and they do so without a foreseen major impact
in treatment delivery time. However, only one of them (75)
clearly demonstrates clinical relevance by comparing SPArc
plans and clinically used IMPT plans in terms of NTCP,
showing a predicted mean reduction of 23% in the probability
of major coronary events caused by a reduction in the heart dose.
Plan robustness must also be considered when discussing
recent developments in proton arc therapy. The general belief is
that proton arc therapy is naturally more robust than IMPT, as it
spreads the range uncertainty among different beam angles (61,
77). Dosimetric studies using SPArc seem to support this
hypothesis: for all reported plans in all five sites, SPArc plans
present equal or better robustness than their IMPT counterparts,
evaluated in terms of mean area under the curve for root-mean-
square dose volume histograms for relevant organs at risk, a
metric introduced by Liu et al. (78).
Another interesting effect linked with PAT is radiobiological
optimization (77). Increasing the number of beam angles allows
for reducing the dose delivered by high-energy beams at the
distal end of the target potentially placing the high-LET
components close to a critical organ. The team at the
University of Pennsylvania recently showed that PMAT plans
effectively increase relative biological effectiveness (RBE) within
the target (68). This finding was validated with an in-vitro study
(79) and has also been reported by other authors in simpler
PAT implementations (80). The clinical relevance of this
radiobiological effect of PAT is yet to be established.
The aforementioned potential benefits of proton arc therapy,
particularly in its SPArc implementation, instigated the
development of a prototype system. A patent from U. of
Maryland described in 2018 a method to deliver a proton
beam while the gantry rotates around the patient, without
changing the energy from the source but using an automatic
energy modulator (81). In 2019, the first delivery of SPArc plans
was reported by the Beaumont team (82) in their IBA Proteus
One accelerator, with a technique that was named ProtonFrontiers in Oncology | www.frontiersin.org 8Dynamic Arc Delivery, or PDAD. The delivered plans reported
passing all quality assurance tests (flatness, symmetry,
isocentricity), and the system was able to deliver a clinical plan
over a 220-degree arc in 4 min.
Further work is required before SPArc (or any other
implementation of PAT) becomes clinically available. The
Beaumont team (82) cite machine stability (beam pauses,
interlocks) and clinical workflow (development of DICOM
standard, integration with TPS and Oncology Information
System, QA program) as the main issues that need to be
resolved. This should be complemented by an improvement in
treatment calculation time, since the current status of the SPArc
dose calculation algorithm, with over 2 h per patient (70), would
hinder its incorporation into a clinical workflow. While recent
developments in the SPArc dose optimization algorithm (83)
have reported some advances, including a ~50% reduction in
estimated irradiation time, a recent study (84) has identified
several inherent weaknesses in the SPArc algorithm and
proposed an alternative approach which can possibly reduce
planning time by up to a factor of 10.
In conclusion, while PAT does not have the disruptive aura of
other advanced technologies (such as FLASH or minibeams), it
can indeed produce a positive effect in the quality of IMPT plans
(due to better dose conformity, increased RBE and enhanced
robustness). However, this effect must be backed up by more
clinical studies. It could improve the logistics of proton
treatments, like VMAT with photons, provided that fast and
accurate treatment planning algorithms are developed. While its
integration with other novel technologies (such as FLASH or
minibeams) has not been studied in detail yet, arc strategies (in
the form of arc-shoot-through techniques) have been proposed
as an intermediate solution for achieving FLASH dose rates with
pencil-beam scanned proton beams (85).
Gantries vs Fixed Beam Treatment
Rooms—The Need for a Change in
Paradigm Enabling Treating Patients in an
Upright Orientation
In a recent paper Bortfeld et al. emphasized the need for particle
beam therapy to become more available to more patients (86,
87). One of the three aspects that they list to “democratize”
protons is to reduce the costs of proton systems by doing away









Demonstrated clinical relevance? Reference
Prostate 9 2.0 No (VMAT) No (71)
Lung 14 1.2 No (IMRT) No (72)
Whole
brain
8 0.9 No (VMAT) No (73)
Head and
neck
14 1.1 No (combination IMPT with
SFUD)**





8 1.1 Yes Mean reduction of 23% in probability of major coronary
events, among other endpoints.
(75)January 2021 | Volume 10 | Art(*) Assuming a value of 1s for energy layer switching time.
(**) X. Ding, private communication. SFUD, Single-field, uniform dose.icle 613669
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the beam. Fixed horizontal beams have been exploited in early
systems to treat the patients in a seated position (88, 89) and at
Fermi Lab, patients were treated in an upright position with
neutrons (90, 91). Seated and upright treatments were until
recently regarded as suboptimal arrangements forced on
proton therapy when it was only available at physics research
institutions, i.e., before the very large, expensive gantry systems
were developed for and installed at hospital based and free-
standing proton therapy clinics.
When the neutron therapy clinical results struggled to live up
to the promises in the early eighties, people in the field reasoned
that it is because they could not achieve the same conformality in
dose than what was possible with gantry-based photon systems.
This was mainly due to the lack of neutron gantries and not
having multileaf collimators to allow for beam shaping to
conform the beam to the target. That argument led to the
development of isocentric neutron gantries and neutron
multileaf collimators.
However, the proton depth dose curve (Bragg Peak) allows for
a different paradigm in delivering the dose to a target. The fact
that the beam stops and that fewer beams are typically used in
proton treatment plans, defeats for some people the argument
that proton gantries are essential. Furthermore, it is true that it’s
better to treat the patient in the same position as what the patient
was scanned in mainly due to the displacement of organs when
the patient is moved from a lying into an upright position.
Intracranial lesions can be, and have been, treated in an upright
position although the patient was scanned in a lying position.
Multimodality imaging is an important aspect of treatment
planning and target delineation and the best registration
between different modality images is obtained with the patient
in the same orientation. Like CT scanners most other imaging
systems, i.e., PET, MRI, PET-CT, gamma Cameras and even
Ultrasound scans are often designed to image the patient in a
lying position. This notion further supports the thinkingFrontiers in Oncology | www.frontiersin.org 9that radiation therapy treatments should be done in the
lying position.
This paradigm is shifting, and several companies are now
developing technologies that will allow for imaging and treating
patients in an upright orientation (companies such as P-Cure,
New-RT Corp Ltd, LEO and Advanced Oncotherapy). In
Figure 3, we show an upright CT scanner and the upright
patient positioner and that is currently being developed by one
of these companies and that will soon be available for integration
into existing proton therapy systems.
Clinical Potential Benefits of Upright Treatments
The potential advantages of treating the patient in a seated or
upright position have been addressed by several scholars in the
field. Verhey et al. reported in 1981 that patients can be
immobilized effectively in the seated position with less
unwanted motions than in a supine or decubitus position (92).
McCarroll et al. reported on the benefits of treating thoracic and
Head and neck patients in a seated position (93). Yang et al.
reported that thoracic patients breathe easier and are more
relaxed in an upright position while the lung volume is on
average up to 25% larger compared to the supine position and
the excursion of a lung tumor as a result of breathing motion is
also smaller (94), depending on the location of the tumor in the
lung. The WHO reported recently that 55% cancer deaths are
from disease sites that are affected by breathing motion (95).
Treating these cases in a seated or upright position could then
result in improved patient comfort, less target motion and less
lung volumes being irradiated.
Among the main benefits of having the patient immobilized
in an upright position we can mention (a) the reduced risk of
asphyxiation and (b) the reduced need to swallow that causes
significant movement in the neck and esophageal regions (93).
Applying anesthesia to patients in the upright position is
common practice, e.g., in shoulder and posterior fossa surgery
and might also be safer in some cases with respect to the risk ofFIGURE 3 | The left panel shows an upright Dual Energy CT scanner together with the upright patient positioner for upright scanning and treatments that is under
development. The right panels show the CT scanner integrated with a CT gurney for CT scanning in the lying down position (courtesy LEO Cancer Care Ltd).January 2021 | Volume 10 | Article 613669
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patients is developed. It also depends on the airway
management as well as the depth of anesthesia. Treating
quadriplegic and paraplegic patients in the upright position
should also be easy since it is standard practice to support
such patients in upright positions for many clinical reasons.
Technical Benefits of Upright Treatments
Upright treatments may offer several technical benefits. Rotating
a 100 to 250 Kg patient isocentrically is mechanically easier than
moving a more than 50T gantry around the patient with the
required precision. This of course means that one needs to focus
on patient comfort and proper immobilization of the patient in
the upright position. In a recent special edition of the British
Journal of radiology (BJR), one of us (96) listed eight beam
delivery specific technologies that proton therapy systems must
be able to offer within the next ten years. Most of these
technologies seems to be more attainable in a fixed beam
configuration for mainly two reasons. Firstly, fixed beam
arrangements provide much more free space around the
isocenter compared to “closed” gantries, and the treatment
envelope around the patient is much more accessible and
predictable. The difference is lower with “open” gantries with
partial isocentric rotation. Furthermore, the beam delivery
nozzle could be retracted further to provide the required space
to implement some of these technologies, e.g., on line axial CT at
isocenter and proton imaging. Second, the fixed beam systems
may be much less expensive, reducing the total project cost and
so the barriers to their purchase.
Cone beam CT (CBCT) images of the patient could easily be
obtained while rotating the patient precisely in a stationary x-ray
beam measuring the transmission x-rays with stationary x-ray
detectors. Proton radiography (P-Rad) and proton computed
tomography (PCT) images can be obtained in a similar manner
providing the proton beam energy is sufficient for the protons to
traverse the specific anatomical region. Upright treatments
require only fixed beam lines which will allow for moving the
scanning magnet further away from the isocenter. This in turn
will allow for faster beam scanning since less scanning power is
required. The benefits of faster scanning are important in terms
of organ motion, FLASH radiation therapy and PAT. Other
benefits of moving the scanning magnet further away from the
isocenter are a larger source to axis distance (SAD) and the
ability to scan the beam to larger field sizes. If a fixed beam
delivery nozzle is equipped with a collapsible vacuum section or a
helium bag smaller spot sizes can be achieved. This will also allow
for variable spots sizes since the beam control does not have to
accommodate variations in the beam optics as a result of changes
in the gantry angle. Implementing fast trimmer apertures would
also be much easier since the gravitational forces on the trimmer
components will be constant (96).
The benefits of upright treatments in reducing the cost of a
proton therapy system seem self-evident. Fixed beams are
cheaper to construct and much easier to maintain as they are
comprised of few and mostly static components. Installing and
commissioning fixed beam systems will also be faster which will
result in significant project cost savings. The shielded volume forFrontiers in Oncology | www.frontiersin.org 10a fixed beam system is much smaller and the wall thicknesses can
be reduced significantly over the bulk of the shielded volume
since the primary beam will only be directed in one direction.
This could allow for optimizing the treatment room layout
resulting in significant cost reductions. The latter could also
allow for improved treatment workflow and throughput
efficiencies. The traditional clinical concerns around upright
treatments could be outweighed by the potential benefits that
upright treatments hold for many patients.DISCUSSION AND CONCLUSIONS: THE
LINK BETWEEN BIOLOGY AND
MECHANICS
In spite of more than 50 years of application of protons, this is
still a highly evolving branch of radiation therapy. It is synergic
with the developments with photon and ion beams. A
multidisciplinary and multicentric approach is necessary to
advance in this field, as it is true for all the tools in the
treatment of cancer.
In this work, we have reviewed aspects that can individually
reduce some of the pitfalls of proton therapy. Even if they seem
to be disconnected (biology and mechanics), some synergies or
incompatibilities can be found between them based on the
described process for each, as represented in Figure 4.
FLASH can reduce the damage to normal tissues under specific
conditions including beam parameters (minimal dose, maximal
time) and oxygenation. Different studies have shown that with the
present devices it is difficult to achieve the technical conditions for
FLASH (85) and even more in large volumes. In the short and
mid-term it can be foreseen that FLASH will apply to treating
smaller volumes close to or embedded in the target volume if the
differential effect of FLASH, between tumoral and healthy cells, is
not only related to oxygen, but also to cellular factors. While this
scenario is the usual one in radiation therapy, specific situations
should also be studied. One example could be re-irradiation in or
close to critical organs, or in vascular areas, to cumulated doses of
110 to 140 Gy, where the risk of necrosis or injuries to vessels are
high and with very different levels of oxygenation.
Minibeams could be applied in synergy with FLASH in order
to avoid any movement, and optimized for large paths through
healthy tissue and applied to small target volumes differentiating
the benefit between tumoral and normal cells or, more
specifically, organs [eg hippocampus, (14)].
In contrast, proton arc therapy is in principle not easily
compatible with minibeams, and can also affect some
mechanisms on the immune response to radiation therapy if
large volumes are irradiated again with low doses.
It is important to conclude mentioning that even among the
co-authors of this review, where we also include personal work of
some of them, there is not a unanimous agreement on the
potential effect of the proposed scenarios, interpretations and
tools. It is not yet known how many logistical and flexible
advantages will be lost without a gantry, how much the pattern
of dose distribution with rotational techniques will change theJanuary 2021 | Volume 10 | Article 613669
Mazal et al. Biomechnical Synergies vs Proton Therapy Pitfallsresponse of tissues, how really mini-beams should be delivered to
keep the tumor control with inhomogeneous dose, and where,
why and how FLASH will be applied efficiently.
If we succeed, with one of these approaches, to reduce at least
one or some of the pitfalls of proton therapy in its present status
(such as cost, complexity, downtime, uncertainties and
complications), it will be even easier to find a better place of
protons as a therapy of choice for treating cancer with radiation
therapy, in a multidisciplinary approach, for a wider population.AUTHOR CONTRIBUTIONS
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